immunity News and Research

RSS

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

A new study in the UK, by researchers at Imperial College London, The Francis Crick Institute and the University of Glasgow, explores the loss of coronavirus disease 2019 (COVID-19) vaccine efficacy against the virus behind the current pandemic caused by the emergence of newer variants that have undergone mutational escape.

30 Jun 2021

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

A new preprint on the medRxiv* server adds fuel to this train of thought, showing that the required cell program is already active in children – namely, a higher expression of specific pattern recognition receptors (PRRs), which mediate an interferon (IFN) response.

30 Jun 2021

Widespread SARS-CoV-2 mutation escapes vaccine- and infection-induced CD8 T-cell responses

Researchers in the UK have warned that a widespread mutation that has arisen in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to escape recognition by CD8 T-cell responses in both convalescent patients and recipients of the current coronavirus disease 2019 (COVID-19) vaccines.

29 Jun 2021

Study offers more evidence that face masks can prevent SARS-CoV-2 transmission

A new study released as a preprint on the medRxiv* server suggests that the use of face masks, of various designs, successfully prevents SARS-CoV-2 transmission. This supports the continued implementation of mask policies in public places until herd immunity is achieved in the region involved.

29 Jun 2021

How is Taiwan tackling its third wave of COVID-19?

The international community has been struggling to predict and contain successive waves of the COVID-19 pandemic, caused by the novel SARS-CoV-2 pathogen. The degree of success has varied between countries. In Taiwan, the use of contact tracing, with testing and isolation of confirmed cases, promises to end the ongoing third wave of the illness within two months. The strategy employed is described in a new preprint available on the medRxiv* server.

29 Jun 2021

How does dexamethasone therapy work in severe COVID-19?

The possible mechanisms that result in dexamethasone being an effective drug against severe SARS-CoV-2 infection are investigated in a new study. The paper’s authors advance the hypothesis that SARS-CoV-2 infection induces cell-specific insensitivity to glucocorticoids, possibly as an unintentional result of the viral replication cycle.

29 Jun 2021

CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease

CN Bio today announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS.

From CN Bio 29 Jun 2021

Tackling emerging SARS-CoV-2 variants

An international team of authors has published a special report in The New England Journal of Medicine titled 'SARS-CoV-2 Variants and Vaccines’, which presents global strategies for the possible escape from vaccine-elicited immunity.

29 Jun 2021

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

One of the key mutations seen in the 'Alpha variant' of SARS-CoV-2 - the deletion of two amino acids, H69/V70 - enables the virus to overcome chinks in its armor as it evolves, say an international team of scientists.

29 Jun 2021

Immune response to FDA-approved vaccines is strong and potentially long-lasting

The first two COVID-19 vaccines authorized for emergency use by the Food and Drug Administration (FDA) employed a technology that had never before been used in FDA-approved vaccines.

29 Jun 2021

What's behind COVID-19 vaccine side effects?

A growing concern among coronavirus vaccines is the vaccine side effects. Fear or misinformation about side effects may fuel vaccine hesitancy, contributing to low vaccination rates. Australian researchers recently published an article in Science Immunology to discuss why people develop side effects and their benefits.

28 Jun 2021

Specific lung cell exhibits immune properties and improves respiratory viral disease outcomes

Researchers at Children's Hospital of Philadelphia have discovered that a specific type of lung cell exhibits unconventional immune properties and may contribute to the outcome of respiratory viral infections.

28 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Anti-cancer prodrug can benefit cancer patients

Unlike conventional cancer drugs that attack and kill cancer cells directly, anti-cancer immunotherapy, which kills cancer cells by strengthening the body's immunity, is a novel type of cancer treatment currently attracting increased attention. Unfortunately, a minority of cancer patients who have some degree of pre-existing immunity only benefit from anti-cancer immunotherapy.

28 Jun 2021

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

A recent study conducted by an international team of scientists has revealed that the Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccine, AZD1222, is capable of inducing strong spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses in vaccinated individuals. A detailed description of AZD1222-induced cellular immunity is currently available on the medRxiv* preprint server.

28 Jun 2021

Why SARS-CoV-2 delta variant is more infectious

German experts recently explained why the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is more infectious and pathogenic than its ancestor. By conducting a series of in vitro experiments, they have revealed that increased ability to induce cell-to-cell fusion (syncytia) and reduced susceptibility to vaccine and infection-induced antibodies make the delta variant more infectious than previously circulating variants. The study is currently available on the bioRxiv* preprint server.

28 Jun 2021

Swedish study reveals how long immunity lasts after mild COVID

As a result of the ongoing pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, the coronavirus disease 2019 (COVID-19), the global public health at risk has never been more dire.

27 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Researchers have described the first reported infection with the C.37 (Lambda) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Southern Brazil.

27 Jun 2021

Georgia Tech’s dashboard breaks down Covid-19 vaccination trends by race at county level

The U.S. continues to see Covid-19 vaccinations gradually increasing nationwide, with nearly 66% of all adults now having at least one vaccine dose according to CDC's COVID Data Tracker, yet disparities have been noted in vaccination rates across races and geographic areas.

25 Jun 2021

immunity News and Research

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

Widespread SARS-CoV-2 mutation escapes vaccine- and infection-induced CD8 T-cell responses

Study offers more evidence that face masks can prevent SARS-CoV-2 transmission

How is Taiwan tackling its third wave of COVID-19?

How does dexamethasone therapy work in severe COVID-19?

CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease

Tackling emerging SARS-CoV-2 variants

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

Immune response to FDA-approved vaccines is strong and potentially long-lasting

What's behind COVID-19 vaccine side effects?

Specific lung cell exhibits immune properties and improves respiratory viral disease outcomes

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Anti-cancer prodrug can benefit cancer patients

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

Why SARS-CoV-2 delta variant is more infectious

Swedish study reveals how long immunity lasts after mild COVID

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Georgia Tech’s dashboard breaks down Covid-19 vaccination trends by race at county level

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News